DEB-TACE Plus Lenvatinib or Sorafenib or PD-1 Inhibitor for Unresectable Hepatocellular Carcinoma

NCT04229355 · clinicaltrials.gov ↗

PHASE3

Phase

UNKNOWN

Status

90

Enrollment

OTHER

Sponsor class

Conditions

Hepatocellular Carcinoma

Interventions

DRUG: DEB-TACE plus Sorafenib
DRUG: DEB-TACE plus Lenvatinib
DRUG: DEB-TACE plus PD-1 inhibitor

Sponsor

Guangxi Medical University